The Business Times
business-time-50
SUBSCRIBERS

Singapore biotech startup Nanyang Biologics bets on AI drug discovery platform to unlock revenue

After investing six years in R&D, the firm is heading to Nasdaq via a US$1.5 billion Spac deal as it lands its first client

Summarise
google-preferred-sourceAdd BT as a preferred source
Tessa Oh

Tessa Oh

Published Wed, Oct 22, 2025 · 09:33 AM
阅读简体中文版 (beta)
    • Dr Roland Ong, founder and chairman of Nanyang Biologics, says: “Biotech, AI and drug discovery are a long-term R&D process and continuous funding is required.”
    • Dr Roland Ong, founder and chairman of Nanyang Biologics, says: “Biotech, AI and drug discovery are a long-term R&D process and continuous funding is required.” PHOTO: TAY CHU YI, BT

    [SINGAPORE] Drug development typically takes six to 10 years just to identify a viable molecule, but Singapore biotech firm Nanyang Biologics reckons it can do the job in six minutes.

    Originally founded as a biopharma startup to develop cancer and cardiovascular therapies, the company simultaneously spent six years building an artificial intelligence (AI) platform to accelerate its own drug discovery work.

    Now it has commercialised that technology as NYB.AI, positioning it as a tool for pharmaceutical and health supplement manufacturers looking to slash costs and timelines.

    Singapore SMEsBiotechStartupArtificial Intelligence

    TRENDING NOW

    The Monetary Authority of Singapore said it is following up with the three Singapore entities to reinforce its expectations of conduct and compliance.

    Tiger Brokers, Moomoo, Longbridge Singapore units ‘financially independent’ amid China crackdown: MAS

    The departure of food manufacturing operations from Singapore may not necessarily be reason for concern.

    Yeo’s, Tiger Beer and now Gardenia – flight of food manufacturing from Singapore might be just as planned

    KSL's Khoo Lee Feng says it is "not so much what you study, but how you learn".

    Johor property old hand KSL readies family handover amid market boom

    Nuclear power “is very much back in the conversation” in Asia, say industry observers.

    As India and China surge ahead with nuclear energy, all eyes on Asean’s next move

    Latest T-bills Treasury Bills Results & Interest NewsLatest SSB Singapore Savings Bonds NewsLatest COE Certificate of Entitlement News
    Latest Johor-Singapore SEZ NewsLatest BTO Build To Order & Sales of Balance NewsLatest STI Straits Times Index NewsLatest SGX Dividends, Share Price NewsLatest Bonds Market NewsLatest Singapore Stocks To Buy NewsLatest Singapore Economy News
    View More